Reach Us +44-1647-403003
Investigation Of Shikonin As A Novel Scar Remediation Therapy | 5097
ISSN: 2157-7013

Journal of Cell Science & Therapy
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Investigation of shikonin as a novel scar remediation therapy

International Conference on Emerging Cell Therapies

Yan Xie, Chen Fan, Ying Dong, Emily Lynam, Kun Li, Yonghua Su and Zee Upton

ScientificTracks Abstracts: J Cell Sci Ther

DOI: 10.4172/2157-7013.S1.002

Z i Cao, a Chinese herb, has been clinically used to treat burns and manage scars in China for thousands of years; however, the pharmacological mechanisms underpinning its reported actions in skin are unclear. Shikonin, an active component extracted from Zi Cao has been demonstrated to induce apoptosis in cancer cell lines. Apoptosis is known to be an essential part of scar tissue remodelling; we therefore hypothesized that Shikonin may induce apoptosis in scar-related cells and this may underpin the successful clinical use of Zi Cao. The effects of Shikonin on skin cell viability, proliferation and collagen metabolism were measured by Alamar Blue, CyQUANT assay and Sirius Red stain, respectively. In addition, Western blot and qRT-PCR were used to detect the changes of protein and gene expression in hypertrophic scar-derived human fibroblasts treated with Shikonin. We present here the first detailed in vitro study examining the effects of Shikonin on the functional responses of scar-related cells, and the mechanisms underlying these responses. Our data suggests that Shikonin inhibits cell viability and proliferation and reduces the amount of collagen present in scar-derived fibroblasts. Further investigation revealed that Shikonin induces apoptosis in scar fibroblasts by differentially regulating caspase 3, Bcl-2, phospho-Erk1/2 and phospho-p38 expression. In addition, Shikonin reduces collagen production in scar fibroblasts by down-regulating collagen I, collagen III and alpha-smooth muscle actin gene expression. In conclusion, we demonstrate that Shikonin induces apoptosis and decreases collagen production in scar fibroblasts and may therefore hold potential as a novel scar remediation therapy
Xie has completed her M.D. in 2004 and Ph.D. in 2008 from Queensland University of Technology (QUT). She was a Research Fellow at QUT and currently she is the head of Skin Repair and Regeneration, Affiliated Hospital of Ningxia Medical University. Dr Xie?s research focus on the development of human skin equivalent wound model and the investigation of novel therapies for wound healing and scar remediation. She has published papers in high ranking journals such as J Invest Dermatol, Tissue Eng and J Control Release. She has been a reviewer for several journals including Molecular Pharmaceutics, Proces Biochemistry and Virology Journal.
Relevant Topics